With 0.17 million shares changed hands, the volume of the stock remained lighter than its average volume of 9.29 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4464 whereas the lowest price it dropped to was $0.4012. The 52-week range on IBO shows that it touched its highest point at $6.17 and its lowest point at $0.37 during that stretch.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IBO was down-trending over the past week, with a drop of -6.93%, but this was down by -21.67% over a month. Three-month performance dropped to -18.42% while six-month performance fell -77.12%.
Float and Shares Shorts:
At present, 12.09 million IBO shares are outstanding with a float of 11.98 million shares on hand for trading. On 2025-05-30, short shares totaled 0.35 million, which was 287.0 higher than short shares on 1745971200. In addition to Mr. Frank D. Heuszel Esq., J.D. as the firm’s Chairman & CEO, Mr. Todd D. Macko CPA serves as its CFO. Secretary & Treasurer.
Institutional Ownership:
Through their ownership of 0.03192 of IBO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, IBO reported revenue of $0.0 and operating income of -$1010000.0. The EBITDA in the recently reported quarter was -$724000.0 and diluted EPS was -$0.11.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
